Compare EJH & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EJH | VRAX |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 1.7M |
| IPO Year | 2019 | 2021 |
| Metric | EJH | VRAX |
|---|---|---|
| Price | $1.60 | $0.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 224.3K | ★ 19.4M |
| Earning Date | 05-18-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.10 |
| 52 Week High | $12.45 | $1.18 |
| Indicator | EJH | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 48.63 |
| Support Level | $0.96 | $0.10 |
| Resistance Level | $1.62 | $0.25 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 2.86 | 49.32 |
E-Home Household Service Holdings Ltd is a household service company providing integrated household services through its website and WeChat platform across China. The company offers services including home appliance and housekeeping services. It operates its business mainly by receiving orders online and providing services offline. Its operations are organized into four reportable segments: appliance installation and maintenance services, housekeeping services, senior care services, and educational consulting services. The company generates the majority of its revenue from installation and maintenance.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.